Mirikizumab
Ulcerative Colitis
Phase 3Active
Key Facts
About Eli Lilly
Eli Lilly is one of the world's largest pharmaceutical companies with over 145 years of experience in developing life-changing medicines. The company has achieved significant recent success with GLP-1 receptor agonists for diabetes and weight management, generating substantial revenue growth. Lilly continues to invest heavily in R&D across key therapeutic areas including diabetes, oncology, autoimmune diseases, and neurodegeneration, with a robust pipeline of innovative treatments in development.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| Filgotinib | Gilead Sciences | Phase 3 |
| Obefazimod (ABX464) | Abivax | Phase 3 |
| Icotrokinra (JNJ-2113) | Protagonist Therapeutics | Phase 3 |
| DE-130 (Etrasimod) | Rohto Pharmaceutical | Phase 3 |
| DE-122 (Carotegrast methyl) | Rohto Pharmaceutical | Phase 3 |
| Methylene Blue MMX® | Cosmo Pharmaceuticals | Preclinical |
| KRP-203 (Amiselimod) | Kissei Pharmaceutical | Phase II |
| EVO301 | Evommune | Phase 1 |
| Pentasa (Mesalazine) | Zeria Pharmaceutical | Approved/Commercial |
| SER-301 | Seres Therapeutics | Phase 1b |
| SER-287 | Seres Therapeutics | Phase 2b |
| IMP731 | Immutep | Phase 2 |